Company Nanoform Finland Oyj Nasdaq Helsinki
Equities
FI4000330972
Biotechnology & Medical Research
Business Summary
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Nanotechnology and Drug Particle Engineering
100.0
%
| 3 | 100.0 % | 3 | 100.0 % | -26.41% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe
57.0
%
| 2 | 56.2 % | 1 | 57.0 % | -25.37% |
United States
43.0
%
| 2 | 43.8 % | 1 | 43.0 % | -27.73% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 01/15/01 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01/15/01 |
Investor Relations Contact | - | 01/19/01 | |
Antonio da Silva
PRN | Corporate Officer/Principal | 50 | 01/19/01 |
Peter Hänninen
LAW | General Counsel | 36 | 01/20/01 |
David Rowe
PRN | Corporate Officer/Principal | 57 | 01/19/01 |
Christian Jones
PRN | Corporate Officer/Principal | 44 | 01/18/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 02/19/02 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 01/19/01 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01/15/01 |
Jeanne A. Thoma
BRD | Director/Board Member | 64 | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 85,445,164 | 59,636,291 ( 69.79 %) | 0 | 69.79 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+28.79% | 4.92TCr | |
+0.76% | 4.21TCr | |
+50.47% | 4.04TCr | |
-5.26% | 2.89TCr | |
+13.18% | 2.61TCr | |
-22.50% | 1.87TCr | |
+8.11% | 1.33TCr | |
+32.17% | 1.23TCr | |
-0.43% | 1.2TCr |